{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:04:50Z","timestamp":1792188290296,"version":"4.4.0"},"reference-count":31,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2020,12,13]],"date-time":"2020-12-13T00:00:00Z","timestamp":1607817600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the efficacy, tolerability, and safety of eptinezumab 100 and 300\u00a0mg compared with placebo in patients with the dual diagnosis of chronic migraine (CM) and medication\u2010overuse headache (MOH).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Eptinezumab, a humanized monoclonal antibody targeting calcitonin gene\u2010related peptide, may be effective for treating patients with a dual diagnosis of CM and MOH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PROMISE\u20102 (NCT02974153) was a double\u2010blind, randomized, placebo\u2010controlled, phase 3 study that comprised a screening visit, a 28\u2010day pretreatment period, and a 32\u2010week study duration. Patients in this exploratory analysis of a prespecified subgroup had confirmed diagnoses of both CM and MOH at screening. Patients were randomly assigned to receive intravenous eptinezumab 100, 300\u00a0mg, or placebo every 12\u00a0weeks. Efficacy outcomes included mean changes from baseline in monthly migraine days (MMDs) during weeks 1\u201312, migraine responder rates at week 12, and percentages of patients below International Classification of Headache Disorders thresholds for CM and MOH over weeks 1\u201324.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There were 431 patients who were diagnosed with CM and MOH as specified in the protocol and received eptinezumab 100\u00a0mg (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a0139), 300\u00a0mg (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a0147), or placebo (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a0145). During the baseline period, these patients experienced an average of 16.7 migraine days across treatment arms. Over weeks 1\u201312, eptinezumab\u2010treated patients experienced greater reductions from baseline in MMDs than placebo patients (100\u00a0mg, change from baseline\u00a0=\u00a0\u22128.4, difference from placebo [95% confidence interval (CI)]\u00a0=\u00a0\u22123.0 [\u22124.56, \u22121.52],\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.0001 vs. placebo; 300\u00a0mg, change from baseline\u00a0=\u00a0\u22128.6, difference from placebo [95% CI]\u00a0=\u00a0\u22123.2 [\u22124.66, \u22121.78],\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.0001 vs. placebo; placebo, \u22125.4). Compared with placebo, more eptinezumab\u2010treated patients were \u226550% migraine responders (100\u00a0mg, 84\/139 [60.4%]; 300\u00a0mg, 91\/147 [61.9%]; placebo, 50\/145 [34.5%]) or \u226575% responders (100\u00a0mg, 38\/139 [27.3%]; 300\u00a0mg, 44\/147 [29.9%]; placebo, 21\/145 [14.5%]) over weeks 1\u201312. Therapeutic benefits with eptinezumab were observed from day 1 after dosing, and improvements were sustained with an additional dose. For the full 24\u2010week treatment period, 71\/139 (51.1%), 80\/147 (54.4%), and 47\/145 (32.4%) of 100, 300\u00a0mg, and placebo\u2010treated patients, respectively, were below CM thresholds, and of the patients who provided sufficient acute medication data, 47\/93 (50.5%), 53\/107 (49.5%), and 26\/96 (27.1%), respectively, were below medication\u2010overuse thresholds.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients diagnosed with both CM and MOH, eptinezumab treatment resulted in greater reductions in MMDs, higher responder rates, and fewer patients meeting CM and MOH criteria, thus demonstrating the efficacy and clinical utility of eptinezumab in this patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.14036","type":"journal-article","created":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T04:34:02Z","timestamp":1607920442000},"page":"125-136","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":93,"title":["Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication\u2010overuse headache: Subgroup analysis of PROMISE\u20102"],"prefix":"10.1111","volume":"61","author":[{"given":"Hans\u2010Christoph","family":"Diener","sequence":"first","affiliation":[{"name":"Institute for Medical Informatics, Biometry and Epidemiology Medical Faculty of the University of Duisburg\u2010Essen Essen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Marmura","sequence":"additional","affiliation":[{"name":"Jefferson Headache Center Thomas Jefferson University Hospitals Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart J.","family":"Tepper","sequence":"additional","affiliation":[{"name":"Department of Neurology Geisel School of Medicine at Dartmouth Hanover NH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Cowan","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurological Sciences Stanford University Headache and Facial Pain Program Palo Alto CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaal J.","family":"Starling","sequence":"additional","affiliation":[{"name":"Department of Neurology Mayo Clinic Scottsdale AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merle L.","family":"Diamond","sequence":"additional","affiliation":[{"name":"Diamond Headache Clinic Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Hirman","sequence":"additional","affiliation":[{"name":"Pacific Northwest Statistical Consulting, Inc. Woodinville WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lahar","family":"Mehta","sequence":"additional","affiliation":[{"name":"Lundbeck Seattle BioPharmaceuticals, Inc. Bothell WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Brevig","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f8rn","family":"Sperling","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Cady","sequence":"additional","affiliation":[{"name":"Lundbeck Seattle BioPharmaceuticals, Inc. Bothell WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,12,13]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0865-z"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30146-2"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2016.12.3.316"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-015-0561-1"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-016-0612-2"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_2_10_8_1","first-page":"365","article-title":"Chronic headache due to overuse of analgesics and anti\u2010migraine agents","volume":"115","author":"Diener HC","year":"2018","journal-title":"Dtsch Arztebl Int"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14268"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413512033"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S46071"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2016.11.071"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32279-7"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2011.03612.x"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000008493"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413515338"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010814-124701"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2018.01.029"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.567"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420905132"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009169"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419858355"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413485658"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.3102\/00346543042003237"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0840-8"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00586"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-015-1636-9"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2013.05.003"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz052"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007497"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007452"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419828994"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14036","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/head.14036","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14036","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:33:25Z","timestamp":1762079605000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.14036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,13]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1111\/head.14036"],"URL":"https:\/\/doi.org\/10.1111\/head.14036","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,13]]},"assertion":[{"value":"2020-08-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}